Anastrozole® Teva 1 mg Tablets (28 Tablets): Product Overview

Understanding the Active Ingredient, Medical Applications, and Safety Profile

Product Introduction

Anastrozole® Teva 1 mg Tablets Online Poland is a prescription medicine containing anastrozole, an active ingredient belonging to the group of medicines known as aromatase inhibitors. This medicine influences the production of oestrogen in the body and has an established role in the treatment of certain hormone-sensitive breast cancers in postmenopausal women.

The product name identifies a tablet strength of 1 mg and a stated pack quantity of 28 tablets. These details help distinguish the product from other anastrozole presentations. However, the exact packaging, manufacturer information, and approved product details should always be checked against the supplied pack and its official documentation.

Understanding the medicine's composition, biological action, intended medical applications, and potential risks provides useful background for patients, caregivers, and healthcare professionals.

Product Composition and Identification

Anastrozole is the active pharmaceutical ingredient responsible for the medicine's principal pharmacological action. Each tablet is described as containing 1 mg of anastrozole, while the stated package contains 28 tablets.

• Product name: Anastrozole® Teva
• Active ingredient: Anastrozole
• Strength: 1 mg per tablet
• Pack size: 28 tablets
• Pharmaceutical form: Tablet, commonly film-coated
• Therapeutic class: Aromatase inhibitor
• Route of administration: Oral
• Product verification: Confirm the original label, batch number, expiry date, and applicable authorisation details.

The precise appearance and inactive ingredients can differ between product presentations and markets. The original package leaflet should therefore be consulted for the details relevant to the particular pack.

What Is Anastrozole?

Anastrozole is a non-steroidal medicine that inhibits aromatase, an enzyme involved in the conversion of certain androgen hormones into oestrogens. Although oestrogens have important physiological functions, some breast cancer cells depend on hormonal stimulation to grow.

After menopause, ovarian oestrogen production decreases considerably. Nevertheless, aromatase activity in tissues such as body fat continues to contribute to the production of oestrogens. Anastrozole reduces this process, lowering oestrogen levels and limiting one of the hormonal pathways that may support the growth of hormone-sensitive breast cancer.

Unlike medicines that primarily block oestrogen receptors, anastrozole acts by reducing the production of oestrogens. This mechanism makes it useful in specific treatment strategies determined by the patient's diagnosis and menopausal status.

Medical Applications

Anastrozole is principally used in the management of hormone receptor-positive breast cancer in postmenopausal women. Its precise indications depend on the applicable prescribing information and the patient's clinical circumstances.

Adjuvant treatment of early breast cancer: Following primary treatment, anastrozole may be prescribed to selected postmenopausal patients with hormone receptor-positive breast cancer. The purpose of adjuvant treatment is to reduce the likelihood of recurrence as part of a broader treatment plan.

Treatment of advanced breast cancer: In appropriate cases, anastrozole may be used to treat advanced hormone-sensitive breast cancer in postmenopausal women. The choice of treatment depends on disease characteristics, previous therapies, and clinical assessment.

Sequential hormonal treatment: Some patients may receive an aromatase inhibitor after completing a period of treatment with another endocrine medicine, such as tamoxifen. Decisions about changing treatment require an assessment of previous therapy, treatment response, and individual risk factors.

Anastrozole is not suitable for every form of breast cancer. Hormone receptor status and menopausal status are important considerations when determining whether this medicine is appropriate.

How Anastrozole Works

The aromatase enzyme helps convert androgen precursors into oestrogens. By inhibiting aromatase, anastrozole reduces the amount of oestrogen produced through this pathway.

For certain breast cancers, lowering oestrogen levels can reduce hormonal stimulation of cancer cells. The medicine therefore acts on a hormonal mechanism associated with tumour growth rather than directly destroying cancer cells.

The clinical benefits depend on the characteristics of the cancer and the individual's response to treatment. Anastrozole is used within a medically supervised treatment plan and does not replace surgery, radiotherapy, or other recommended treatments when these are indicated.

Understanding the 1 mg Strength and Pack Size

The stated strength of 1 mg refers to the quantity of anastrozole in each tablet. The pack size of 28 tablets indicates the number of tablets supplied, not the recommended duration of treatment.

Treatment schedules and duration depend on the diagnosis, the stage of disease, the patient's response, and the prescribing clinician's assessment. The quantity supplied should not be used independently to determine a treatment schedule.

Before the medicine is used, the product name, strength, ingredient information, expiry date, and batch identification should be checked. Any uncertainty about the packaging or the identity of the medicine should be discussed with a pharmacist.

Possible Side Effects

Anastrozole can cause adverse effects because reducing oestrogen levels may influence several body systems. The nature and severity of these effects vary between individuals.

Reported side effects include:

• Hot flushes and increased sweating.
• Joint pain, stiffness, and muscle discomfort.
• Headaches and tiredness.
• Nausea and digestive disturbances.
• Skin reactions.
• Changes in mood or sleep.
• Reduced bone mineral density and increased fracture risk.
• Changes in cholesterol levels.

This list is not exhaustive. Patients should report persistent or troublesome symptoms to their healthcare professional. Chest pain, sudden difficulty breathing, or signs of a severe allergic reaction require urgent medical assessment.

Bone Health and Ongoing Monitoring

Oestrogen plays an important role in maintaining bone strength. Prolonged reduction in oestrogen levels may contribute to decreased bone mineral density and increase the risk of osteoporosis or fractures.

A clinician may assess existing bone-health risks and recommend bone-density testing when appropriate. Dietary calcium, vitamin D intake, and suitable physical activity may also form part of an individual care plan.

Monitoring can include assessment of treatment response, adverse effects, cholesterol levels, and other health indicators when clinically necessary. Regular follow-up helps healthcare professionals evaluate the balance between treatment benefits and potential risks.

Precautions and Medicine Interactions

Anastrozole is not appropriate for everyone. Standard product information advises against its use in premenopausal women for the established breast cancer indications and during pregnancy or breastfeeding. It is also unsuitable for individuals with a known serious hypersensitivity to anastrozole or relevant ingredients.

Patients should tell their healthcare professional about liver conditions, existing cardiovascular disease, osteoporosis, allergies, and all other relevant medical conditions.

Tamoxifen and oestrogen-containing medicines can interfere with the intended action of anastrozole. A healthcare professional should review all prescription medicines, non-prescription products, vitamins, supplements, and hormonal treatments before use.

Anastrozole should only be used according to the prescribed treatment plan. Patients should not start, stop, or change treatment without consulting their prescribing clinician.

Storage and Product Authenticity

The storage instructions printed on the original packaging should be followed. Keep the tablets in the recommended packaging, protect them from unsuitable environmental conditions, and store the medicine securely out of children's reach. Do not use tablets beyond their expiry date or if the packaging appears damaged or compromised.

The name Anastrozole® Teva and the stated pack size do not independently establish the authenticity or